Clinical trial
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast…
NCT00060138 · Chugai Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00060138 |
|---|---|
| Title | Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases |
| Official title | A Phase I-II, 24-Week, Multi-Center, Double-Blind, Randomized, Dose-Ranging Study To Evaluate The Safety And Efficacy Of A Humanized Monoclonal Antibody To PTHrP Versus Zoledronic Acid In Patients With Breast Cancer Metastatic To Bone |
| Lead sponsor | Chugai Pharmaceutical, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain |
| Intervention type | Biological, Drug |
| Interventions | monoclonal antibody CAL, zoledronic acid |
| Start date | Nov 1, 2002 |
| Primary completion | Sep 1, 2004 |
| First posted | May 7, 2003 |
| Last update posted | May 15, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: